scispace - formally typeset
B

Brian Pulliam

Researcher at Harvard University

Publications -  13
Citations -  3165

Brian Pulliam is an academic researcher from Harvard University. The author has contributed to research in topics: Spray drying & Gene expression profiling. The author has an hindex of 8, co-authored 13 publications receiving 2973 citations. Previous affiliations of Brian Pulliam include University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum

TL;DR: Analysis of the complete asexual intraerythrocytic developmental cycle (IDC) transcriptome of the HB3 strain of P. falciparum demonstrates that this parasite has evolved an extremely specialized mode of transcriptional regulation that produces a continuous cascade of gene expression, beginning with genes corresponding to general cellular processes, such as protein synthesis, and ending with Plasmodium-specific functionalities.
Journal ArticleDOI

Nanoparticles for drug delivery to the lungs.

TL;DR: Novel methods formulating nanoparticles into the form of micron-scale dry powders have been developed, which exhibit improved handling and delivery, while releasing nanoparticles upon deposition in the lungs.
Journal ArticleDOI

The gene expression signatures of melanoma progression

TL;DR: The results suggest that melanoma pathogenesis can be understood as a series of distinct molecular events, and the gene expression signatures identified here provide the basis for developing new diagnostics and targeting therapies for patients with malignant melanoma.
Journal ArticleDOI

Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray

TL;DR: DNA microarrays based on long oligonucleotides are powerful tools for the functional annotation and exploration of the P. falciparum genome and may serve as the basis for future drug targets and vaccine development.
Journal ArticleDOI

Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route

TL;DR: The disadvantages observed with the existing hepatitis B vaccine administered by the parenteral route may be overcome by administering them as novel dry powders to the lungs, which have the advantage of eliciting a high mucosal immune response in the lungs without traditional adjuvants.